Phase II study of first-line 131I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic 18F-fluorodeoxyglucose positron emission tomography

Andrew Mcquillan, Will Macdonald, J Turner

    Research output: Contribution to journalArticle

    10 Citations (Scopus)

    Fingerprint Dive into the research topics of 'Phase II study of first-line <sup>131</sup>I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic <sup>18</sup>F-fluorodeoxyglucose positron emission tomography'. Together they form a unique fingerprint.

    Medicine & Life Sciences